| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Abiraterone acetate (AA) in pre- and post-docetaxel (DX) setting for metastatic castration resistant prostate cancer (mCRPC): a monoinstitutional experience focused on cardiovascular events and on their impact on clinical outcomes
|
Boccardo, F.
|
|
|
28 |
S6 |
p. vi22
|
artikel
|
| 2 |
Access of the oncologic patients to the emergency room of the local hospital during the three-year period 2014–2016
|
vitello, S.
|
|
|
28 |
S6 |
p. vi99
|
artikel
|
| 3 |
A circulating miRNA signature to better stratify prostate cancer patients at diagnosis
|
Roberg Sita-Lumsden, A.
|
|
|
28 |
S6 |
p. vi21
|
artikel
|
| 4 |
Addressing the best treatment for non-clear cell renal cell carcinoma (nccRCC): a meta-analysis of randomized clinical trials comparing VEGFR-TKis versus mTORi targeted therapies
|
Ciccarese, C.
|
|
|
28 |
S6 |
p. vi18
|
artikel
|
| 5 |
Adjuvant treatment in elderly cancer patients: a multicenter real-life experience
|
Bassanelli, M.
|
|
|
28 |
S6 |
p. vi97-vi98
|
artikel
|
| 6 |
Aflibercept efficacy according to sidedness, RAS and BRAF mutations. Findings from the VELOUR trial in second line therapy of advanced colorectal cancer patients
|
Maiello, E.
|
|
|
28 |
S6 |
p. vi7
|
artikel
|
| 7 |
Aflibercept in combination with FOLFIRI for the 2nd-line treatment of patients with metastatic colorectal cancer (MCRC): safety data from a single institute experience
|
Muntoni, M.
|
|
|
28 |
S6 |
p. vi15
|
artikel
|
| 8 |
Alopecia/hair loss in all patients treated with trastuzumab and paclitaxel: myth or reality?
|
Loparco, D.
|
|
|
28 |
S6 |
p. vi42
|
artikel
|
| 9 |
A Multigene Score based on gene-expression profiling as a prognostic tool in women with early stage, hormone receptor-positive/Her2-negative breast cancer
|
Conte, B.
|
|
|
28 |
S6 |
p. vi25
|
artikel
|
| 10 |
Analysis of clinical outcomes according to mutation subtype in EGFR-positive advanced non-small cell lung cancer (aNSCLC) patients treated with EGFR Tyrosine Kinases Inhibitors (TKIs) as first line
|
Veccia, A.
|
|
|
28 |
S6 |
p. vi64
|
artikel
|
| 11 |
Analysis of DPYD and UGT1A1 genotype in patients with advanced pancreatic cancer treated with modified FOLFIRINOX
|
Vivaldi, C.
|
|
|
28 |
S6 |
p. vi48
|
artikel
|
| 12 |
Analysis of miRNAs and their correlation with early malignat melanoma (MM)
|
Occelli, M.
|
|
|
28 |
S6 |
p. vi69
|
artikel
|
| 13 |
Ang-2 polymorphisms in relation to outcome in advanced HCC patients receiving sorafenib
|
Casadei Gardini, A.
|
|
|
28 |
S6 |
p. vi46
|
artikel
|
| 14 |
Anti HER2 treatment (H) in the elderly: a “real life” retrospective analysis
|
Malossi, A.
|
|
|
28 |
S6 |
p. vi43
|
artikel
|
| 15 |
A phase II trial of dacomitinib in locally advanced unresectable or metastatic skin squamous cell carcinoma
|
Bossi, P.
|
|
|
28 |
S6 |
p. vi68
|
artikel
|
| 16 |
A propensity score analysis exploring the impact of adjuvant chemotherapy (aCT) in 739 patients (pts) affected by early stage pure Invasive Lobular breast Carcinoma (ILC)
|
Carbognin, L.
|
|
|
28 |
S6 |
p. vi27
|
artikel
|
| 17 |
Are anti-HER2 agents the best choice in metastatic breast cancer with an HER2 positive switch from primary tumour? A retrospective multi institution analysis of clinical-pathological characteristics and outcomes
|
Bertolini, I.
|
|
|
28 |
S6 |
p. vi42-vi43
|
artikel
|
| 18 |
A retrospective analysis of patients (pts) with non-small-cell lung cancer (NSCLC) with uncommon or complex epidermal growth factor receptor (EGFR) mutations treated with tyrosine kinase inhibitors (EGFR-TKIs): clinical features and outcome
|
Stasi, I.
|
|
|
28 |
S6 |
p. vi56
|
artikel
|
| 19 |
ARIEL4: An international, randomised phase 3 study of rucaparib vs chemotherapy as treatment for BRCA1- or BRCA2-mutated, relapsed ovarian cancer
|
Lorusso, D.
|
|
|
28 |
S6 |
p. vi71
|
artikel
|
| 20 |
Arterially directed embolic therapy (ADET) with polyethylene glycol microspheres loaded with irinotecan for refractory liver metastases from colorectal cancer
|
Fiorentini, G.
|
|
|
28 |
S6 |
p. vi12
|
artikel
|
| 21 |
A single institution twenty-year experience of recurrent or metastatic epithelial non glandular sinonasal cancer
|
Cavalieri, S.
|
|
|
28 |
S6 |
p. vi74
|
artikel
|
| 22 |
Assessing the risk of pelvic and para-aortic nodal involvement in apparent early-stage ovarian cancer: a predictors- and nomogram-based analyses
|
Bogani, G.
|
|
|
28 |
S6 |
p. vi70
|
artikel
|
| 23 |
Assessment of critical factors related to return to work in women after breast cancer
|
Giordani, S.
|
|
|
28 |
S6 |
p. vi31
|
artikel
|
| 24 |
Association between the development of autoimmune hypothyroidism and objective response to nivolumab: report of two cases
|
Di Lucca, G.
|
|
|
28 |
S6 |
p. vi99
|
artikel
|
| 25 |
ASTRIS, a real world treatment study of osimertinib in patients (pts) with EGFR T790M positive non-small cell lung cancer (NSCLC): preliminary analysis of the Italian cohort
|
Passaro, A.
|
|
|
28 |
S6 |
p. vi54
|
artikel
|
| 26 |
“At home without pain”: a national project on real time pain monitoring system in advanced cancer patients assisted at home by the ANT Foundation
|
Martoni, A.
|
|
|
28 |
S6 |
p. vi103
|
artikel
|
| 27 |
A try to positively influence the quality of life of patients undergoing stem cell transplantation in protective isolation with the use of a tablet
|
Scala, V.
|
|
|
28 |
S6 |
p. vi111-vi112
|
artikel
|
| 28 |
Author index
|
|
|
|
28 |
S6 |
p. vi113-vi125
|
artikel
|
| 29 |
Bald is beautiful: no more. The stigma of alopecia during chemotherapy: Brindisi Oncology Department experience
|
Lutrino, E.S.
|
|
|
28 |
S6 |
p. vi40-vi41
|
artikel
|
| 30 |
Baseline absolute neutrophil count (ANC), derived neutrophil-to-lymphocyte ratio (dNLR) and platelet-to-lymphocyte ratio (PLR) and outcome in non small cell lung cancer (NSCLC) treated with nivolumab or docetaxel: a preliminary analysis
|
Russo, A.
|
|
|
28 |
S6 |
p. vi61
|
artikel
|
| 31 |
Baseline characteristics of cancer Patients demanding integrative oncology (IO) support. The experience of Nuova Oncologia Integrata (NOI), an Italian non-profit organization
|
Bidin, L.
|
|
|
28 |
S6 |
p. vi91
|
artikel
|
| 32 |
Biliary tract carcinoma and chronic viral hepatitis in Italy: the GICO (Gruppo Italiano COlangiocarcinoma) experience
|
Filippi, R.
|
|
|
28 |
S6 |
p. vi46
|
artikel
|
| 33 |
Biological and clinical effects of abemaciclib in a phase 2 neoadjuvant study for postmenopausal patients with HR+/HER2- breast cancer
|
Guarneri, V.
|
|
|
28 |
S6 |
p. vi25
|
artikel
|
| 34 |
Bladder-sparing trimodality approach for unfit for surgery and cisplatin treatment elderly patients with muscle-invasive bladder cancer (MIBC): results from a monocentric experience
|
Rozzi, A.
|
|
|
28 |
S6 |
p. vi19-vi20
|
artikel
|
| 35 |
Blood stream infection in cancer patients—device management and epidemiology: the BSIDE study
|
Cortiula, F.
|
|
|
28 |
S6 |
p. vi96-vi97
|
artikel
|
| 36 |
Bone health management in early breast cancer patients: an Italian Osteoncology Center experience
|
Recine, F.
|
|
|
28 |
S6 |
p. vi25-vi26
|
artikel
|
| 37 |
Bone pain control in Castration resistant prostate cancer (CRPC): retrospective analysis of first patients trated with Radium 223
|
Toma, I.
|
|
|
28 |
S6 |
p. vi24
|
artikel
|
| 38 |
Brain metastases and ado-trastuzumab emtansine (TDM-1) treatment in HER2 positive metastatic patients: an Italian multicenter analysis
|
Fabi, A.
|
|
|
28 |
S6 |
p. vi27
|
artikel
|
| 39 |
Brain radiotherapy (RT) and immunotherapy (IT) for metastatic melanoma (MM): a retrospective single institution experience
|
Galli, G.
|
|
|
28 |
S6 |
p. vi68
|
artikel
|
| 40 |
BRCA1/BRCA2 mutations in a Mediterranean population (Apulia Region) with breast or ovarian cancer: a single center experience
|
Caloro, M.
|
|
|
28 |
S6 |
p. vi32
|
artikel
|
| 41 |
BRCA related breast cancer and sporadic tumors: same prognosis or survivorship bias?
|
Ballatore, Z.
|
|
|
28 |
S6 |
p. vi28
|
artikel
|
| 42 |
Breakthrough-pain likelihood scoring system in cancer patients
|
Gunnellini, M.
|
|
|
28 |
S6 |
p. vi102
|
artikel
|
| 43 |
Breast cancer secondary prevention: get fit to feel healthy
|
Pistelli, M.
|
|
|
28 |
S6 |
p. vi80-vi81
|
artikel
|
| 44 |
Breast unit and caring, gordon nursing model and NNN taxonomies: the nursing care planning from efficacy in trials to effectiveness in clinical practice
|
Bertocchi, L.
|
|
|
28 |
S6 |
p. vi110
|
artikel
|
| 45 |
Broad immunomodulating effect of first-line Pazopanib in metastatic renal cell carcinoma patients
|
Verzoni, E.
|
|
|
28 |
S6 |
p. vi17
|
artikel
|
| 46 |
BTcP: Retrospective study on integrated hospital care between palliative care clinical and oncologist
|
Defferrari, C.
|
|
|
28 |
S6 |
p. vi102
|
artikel
|
| 47 |
CabaCy—evaluating Cabazitaxel efficaCy by patterns of treatment and disease in metastatic castration resistant prostate cancer (mCRPC) patients: a 5 years, “Real Life”, mono-institutional experience
|
Rossetti, S.
|
|
|
28 |
S6 |
p. vi21-vi22
|
artikel
|
| 48 |
Cancer as family disease
|
Bertagnini, L.
|
|
|
28 |
S6 |
p. vi86
|
artikel
|
| 49 |
Cancer care for migrant patients: the value of a dedicated service
|
Casolino, R.
|
|
|
28 |
S6 |
p. vi87
|
artikel
|
| 50 |
Cancer, emotions, and cinema: a preliminary study about the changes experienced by oncological patients
|
Sarno, L.
|
|
|
28 |
S6 |
p. vi87
|
artikel
|
| 51 |
Cancer related fatigue in adults, adolescents and children. Literature review
|
Rizzo, E.M.
|
|
|
28 |
S6 |
p. vi110
|
artikel
|
| 52 |
Can the salivary microRNA expression profile help to identify novel biomarkers for oral squamous cell carcinoma detection?
|
Maragliano, R.
|
|
|
28 |
S6 |
p. vi73
|
artikel
|
| 53 |
Can the use of clinical decision support system (CDSS) affect the number of adverse drug reaction (ADR) reports in the oncological patient? A preliminary evaluation of the status quo in Reggio Emilia Oncological Center (CORE) and future perspectives
|
longobardi, C.
|
|
|
28 |
S6 |
p. vi97
|
artikel
|
| 54 |
Cardiac safety of adjuvant non-pegylated liposomal doxorubicin combined with cyclophosphamide and followed by paclitaxel in older breast cancer patients
|
Coltelli, L.
|
|
|
28 |
S6 |
p. vi41
|
artikel
|
| 55 |
Cardiovascular disease (CVD) markers in patients(pts) with prostate cancer(PCa) treated with GN-RH agonists(AG) or antagonist(AN): a prospective cohort study
|
Cavo, A.
|
|
|
28 |
S6 |
p. vi21
|
artikel
|
| 56 |
Changes in alkaline phosphatase (ALP) dynamics and overall survival (OS) in metastatic castration-resistant prostate cancer (mCRPC) patients treated with radium-223 in an international early access program (EAP)
|
Procopio, G.
|
|
|
28 |
S6 |
p. vi19
|
artikel
|
| 57 |
Circulating angiogenesis-related markers as predictors of benefit from regorafenib in metastatic colorectal cancer (mCRC) patients (pts)
|
Antoniotti, C.
|
|
|
28 |
S6 |
p. vi4
|
artikel
|
| 58 |
Circulating immune-profile as predictor of outcome in advanced NSCLC patients treated with Nivolumab
|
Tiseo, M.
|
|
|
28 |
S6 |
p. vi60
|
artikel
|
| 59 |
Circulating programmed death ligand-1 (PD-L1) in non-small cell lung cancer (NSCLC)
|
Vecchiarelli, S.
|
|
|
28 |
S6 |
p. vi62
|
artikel
|
| 60 |
Cisplatin in addition to single-agent first-line chemotherapy in elderly patients with advanced non-small-cell lung cancer (NSCLC): efficacy results of a joint analysis of the multicentre, randomized phase 3 MILES-3 and MILES-4 studies
|
Morabito, A.
|
|
|
28 |
S6 |
p. vi2
|
artikel
|
| 61 |
Clinical features of never smoker patients with lung squamous cell carcinoma: a retrospective multicenter study
|
Frega, S.
|
|
|
28 |
S6 |
p. vi60
|
artikel
|
| 62 |
Clinical results of the effectiveness of verbal versus written and verbal information about nausea and vomiting in patients receiving chemotherapy
|
Mazzega Fabbro, C.
|
|
|
28 |
S6 |
p. vi108
|
artikel
|
| 63 |
Clinical trials and risk-based approach: reality or Utopia?
|
Cagnazzo, C.
|
|
|
28 |
S6 |
p. vi97
|
artikel
|
| 64 |
Clinical use of immune-checkpoint inhibitors: focus on late immune-related adverse events and pseudoprogression
|
Sini, C.
|
|
|
28 |
S6 |
p. vi63
|
artikel
|
| 65 |
Colon-rectal follow-up program: a monocentric experience
|
Stratta, E.
|
|
|
28 |
S6 |
p. vi13
|
artikel
|
| 66 |
Colorectal cancer (CRC) progression and angiogenesis: tumor infiltrating natural killer cells as novel inflammatory orchestrators
|
Albini, A.
|
|
|
28 |
S6 |
p. vi11-vi12
|
artikel
|
| 67 |
Combination of duligotuzumab, anti HER3 antibody or taselisib, PI3K INhibitor with trastuzumab shows synergetic antitumoral activity in HER2 positive gastric cancer cells
|
Laterza, M.M.
|
|
|
28 |
S6 |
p. vi48
|
artikel
|
| 68 |
Combination of nivolumab (nivo) + ipilimumab (ipi) in the treatment of patients (pts) with deficient DNA mismatch repair (dMMR)/high microsatellite instability (MSI-H) metastatic colorectal cancer (mCRC): CheckMate 142 Study
|
Lonardi, S.
|
|
|
28 |
S6 |
p. vi3
|
artikel
|
| 69 |
Comorbidity scores as predictive tools for nivolumab toxicity in patients with advanced non small cell lung cancer (NSCLC): preliminary results of a prospective multicenter study
|
Quaquarini, E.
|
|
|
28 |
S6 |
p. vi60
|
artikel
|
| 70 |
Comparative effects of Folfirinox and Gemcitabine/nab-paclitaxel as first and second line chemotherapy for metastatic pancreatic cancer: single choice or sequence
|
Caponnetto, S.
|
|
|
28 |
S6 |
p. vi51
|
artikel
|
| 71 |
CompLEEment-1: phase 3b study of ribociclib + letrozole for the treatment of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (ABC) in patients with no prior endocrine therapy (ET) for ABC
|
Zamagni, C.
|
|
|
28 |
S6 |
p. vi39-vi40
|
artikel
|
| 72 |
Compliance to diagnostic and therapeutic pathways and innovative drug recommendations in advanced non-small cell lung cancer: preliminary results from the MOST study
|
Pasello, G.
|
|
|
28 |
S6 |
p. vi57
|
artikel
|
| 73 |
Concomitant versus sequential Fotemustine and Bevacizumab in recurrent malignant gliomas: treatment response and survival outcomes in a retrospective analysis
|
Prelaj, A.
|
|
|
28 |
S6 |
p. vi77
|
artikel
|
| 74 |
CORE-URO-01 study: comparison of safety and efficacy of pazopanib in first-line metastatic renal cell carcinoma (mRCC) with or without renal failure
|
Masini, C.
|
|
|
28 |
S6 |
p. vi17
|
artikel
|
| 75 |
Correlation of PD-L1 staining between primitive tumor and metastasis in advanced colorectal cancer patients
|
Tampellini, M.
|
|
|
28 |
S6 |
p. vi8
|
artikel
|
| 76 |
Cost-effectiveness of a cancer diagnosis on frail elderly cancer patients
|
Luciani, A.
|
|
|
28 |
S6 |
p. vi101
|
artikel
|
| 77 |
Cost-effectiveness of anti-angiogenic agents in second-line treatment for metastatic colorectal cancer. Integrating the EUROPEAN Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS) with the costs of drugs
|
Giuliani, J.
|
|
|
28 |
S6 |
p. vi6
|
artikel
|
| 78 |
CREAM study: Clinical correlation between immunotherapy-RElated colitis And intestinal Microbiote in metastatic patients
|
Orgiano, L.
|
|
|
28 |
S6 |
p. vi100-vi101
|
artikel
|
| 79 |
Crizotinib in ROS1 rearranged or MET deregulated non-small-cell lung cancer (NSCLC): final results of the METROS trial
|
Landi, L.
|
|
|
28 |
S6 |
p. vi54
|
artikel
|
| 80 |
“Cure alopecia”: results on the first period of use of the Dignicup system in the AORMN
|
Campanelli, T.
|
|
|
28 |
S6 |
p. vi111
|
artikel
|
| 81 |
Development and psychometric testing of a measure of perception of care dependency in cancer patients
|
Piredda, M.
|
|
|
28 |
S6 |
p. vi105-vi106
|
artikel
|
| 82 |
Dietary habits in women with breast cancer in treatment with endocrine therapy: a review of letterature
|
El Sayed, S.
|
|
|
28 |
S6 |
p. vi109-vi110
|
artikel
|
| 83 |
Differential gene expression patterns in HER2 positive metastatic breast cancer patients according to hormone receptor status
|
Omarini, C.
|
|
|
28 |
S6 |
p. vi38-vi39
|
artikel
|
| 84 |
Different signatures of HPV-related oropharynx cancer (OPC) correlate with patients outcome
|
De Cecco, L.
|
|
|
28 |
S6 |
p. vi73
|
artikel
|
| 85 |
Dignity Therapy: a new psychoterapeutic approach for people facing advanced disease
|
Andreis, F.
|
|
|
28 |
S6 |
p. vi86
|
artikel
|
| 86 |
Dihydropyrimidine dehydrogenase (DPD) deficiency: how to translate it in clinical practice?
|
Adua, D.
|
|
|
28 |
S6 |
p. vi12-vi13
|
artikel
|
| 87 |
Dissecting primary resistance to anti-EGFRs in RAS and BRAF wt metastatic colorectal cancer (mCRC): A case-control study
|
Rossini, D.
|
|
|
28 |
S6 |
p. vi4
|
artikel
|
| 88 |
Distress in the hospitalized oncological patient: a study observation
|
De Domenico, R.
|
|
|
28 |
S6 |
p. vi106-vi107
|
artikel
|
| 89 |
DNA amount comparison between cytologic and histologic samples for epithelial growth factor receptor (EGFR) testing in non-small-cell lung cancer (NSCLC) patients: a single institution experience
|
Gobbini, E.
|
|
|
28 |
S6 |
p. vi58
|
artikel
|
| 90 |
Docetaxel and ifosfamide as salvage treatment in EGFR, ALK wilde type non small cell lung cancer (NSCLC)
|
Mancarella, S.
|
|
|
28 |
S6 |
p. vi63
|
artikel
|
| 91 |
Does bevacizumab plus chemotherapy matter in metastatic colorectal cancer patients with mucinous histology? A multicenter, retrospective analysis on 685 patients
|
Catalano, V.
|
|
|
28 |
S6 |
p. vi3
|
artikel
|
| 92 |
Does dose modification affect efficacy of first-line pazopanib in metastatic renal cell carcinoma?
|
Fuca', G.
|
|
|
28 |
S6 |
p. vi20
|
artikel
|
| 93 |
Does second-line therapy affect the outcome of the patients with cholangiocarcinoma? A single institution experience
|
Gurrieri, L.
|
|
|
28 |
S6 |
p. vi52
|
artikel
|
| 94 |
Early assessment of chemotherapy-related cardiovascular toxicity in patients with breast cancer
|
Daffinà, M.G.
|
|
|
28 |
S6 |
p. vi38
|
artikel
|
| 95 |
Early changes in plasma levels of mutant KRAS DNA as a sensitive marker of response to chemotherapy in pancreatic cancer
|
Del Re, M.
|
|
|
28 |
S6 |
p. vi47
|
artikel
|
| 96 |
Early loss of skeletal muscle mass (LSMM) as prognostic factor in metastatic pancreatic cancer (PC) patients
|
Basile, D.
|
|
|
28 |
S6 |
p. vi49
|
artikel
|
| 97 |
Early male breast cancer: a single center experience
|
Grigioni, E.
|
|
|
28 |
S6 |
p. vi41-vi42
|
artikel
|
| 98 |
Economic burden of cancer: a population-based cost analysis
|
Altini, M.
|
|
|
28 |
S6 |
p. vi95
|
artikel
|
| 99 |
Editorial board
|
|
|
|
28 |
S6 |
p. ii-iii
|
artikel
|
| 100 |
Effectiveness of cryotherapy in prevention and control of chemotherapy-induced oral mucositis
|
Auletta, G.
|
|
|
28 |
S6 |
p. vi108
|
artikel
|
| 101 |
Efficacy and patient acceptability of the DigniCaP ScalpCooler to prevent hair loss in breast cancer patients receiving adjuvant chemotherapy
|
Carla, F.
|
|
|
28 |
S6 |
p. vi107
|
artikel
|
| 102 |
Efficacy and safety of everolimus and exemestane for metastatic breast cancer patients: a real-life experience of three Oncology Departments
|
Meattini, I.
|
|
|
28 |
S6 |
p. vi42
|
artikel
|
| 103 |
Efficacy and safety of immune checkpoint inhibitor nivolumab and radiotherapy combination in advanced NSCLC
|
Belluomini, L.
|
|
|
28 |
S6 |
p. vi64
|
artikel
|
| 104 |
Efficacy and safety of Nab-paclitaxel plus gemcitabine in metastatic pancreatic cancer
|
Filipazzi, V.
|
|
|
28 |
S6 |
p. vi53
|
artikel
|
| 105 |
Efficacy and safety of the combination of pertuzumab (P) plus trastuzumab (T) plus docetaxel (D) for HER-2 positive metastatic breast cancer (MBC) in pretreated patients (pts) with trastuzumab in the neo/adjuvant setting: a retrospective real-life study
|
Ricciardi, G.
|
|
|
28 |
S6 |
p. vi41
|
artikel
|
| 106 |
Efficacy of anti-EGFR antibodies combined with chemotherapy for elderly patients with RAS wild-type metastatic colorectal cancer: a systematic review and metanalysis
|
Carandina, I.
|
|
|
28 |
S6 |
p. vi8
|
artikel
|
| 107 |
Efficacy of ceritinib administered to patients with crizotinib-refractory, ALK-positive, advanced NSCLC within the Italian compassionate use program
|
Metro, G.
|
|
|
28 |
S6 |
p. vi56-vi57
|
artikel
|
| 108 |
Efficacy of cryotherapy in paclitaxel-induced nail toxicity: Final results from a Phase II Clinical Study
|
Biasotto, V.
|
|
|
28 |
S6 |
p. vi105
|
artikel
|
| 109 |
Efficacy of extended aromatase inhibitors for hormone-receptor–positive breast cancer: a literature based meta-analysis of randomized trials
|
Roviello, G.
|
|
|
28 |
S6 |
p. vi34
|
artikel
|
| 110 |
Efficacy of neurokinin-1 receptor antagonists in the prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in patients receiving carboplatin-based chemotherapy: a systematic review and meta-analysis
|
Di Maio, M.
|
|
|
28 |
S6 |
p. vi90
|
artikel
|
| 111 |
Efficacy of pertuzumab in combination with trastuzumab and a taxane in in first line treatment for metastatic breast cancer (MBC): a multicenter retrospective observational study
|
Mentuccia, L.
|
|
|
28 |
S6 |
p. vi26
|
artikel
|
| 112 |
Efficacy of platinum-based chemotherapy in EGFR WT nonsquamous advanced non-small cell lung cancer (NSCLC) patients: association with KRAS mutation and thymidylate synthase (TS) levels
|
Ricciuti, B.
|
|
|
28 |
S6 |
p. vi58-vi59
|
artikel
|
| 113 |
EGFR mutational status in determining choice of TKIs or standard chemotherapy for patients with advanced non-small cell lung cancer
|
Motta, L.
|
|
|
28 |
S6 |
p. vi63
|
artikel
|
| 114 |
EGFR status evaluation by liquid biopsy during first-line therapy in advanced NSCLC patients
|
Pagano, M.
|
|
|
28 |
S6 |
p. vi62
|
artikel
|
| 115 |
Elderly patients and metastatic soft tissue sarcomas (STS): a monoinstitutional experience
|
Comandone, A.
|
|
|
28 |
S6 |
p. vi66
|
artikel
|
| 116 |
Elderly patients with lung cancer: does clinical practice reflect evidence-based medicine? our four-year experience (2013-2016)
|
Arnoldi, E.
|
|
|
28 |
S6 |
p. vi64-vi65
|
artikel
|
| 117 |
Electrochemotherapy in the treatment of cutaneous metastases from breast cancer: a multicenter cohort analysis
|
Guida, M.
|
|
|
28 |
S6 |
p. vi40
|
artikel
|
| 118 |
Enzalutamide (E) vs abiraterone acetate (AA) in the treatment of metastatic, castration-resistant prostate cancer. Indirect comparisons and network meta-analysis for clinical practice
|
Bianchi, E.
|
|
|
28 |
S6 |
p. vi20
|
artikel
|
| 119 |
Eph A2 expression is a predictive biomarker of poorer activity and efficacy of FOLFIRI + cetuximab in RAS WT metastatic colorectal cancer (mCRC) patients (pts) in the CAPRI GOIM trial
|
Cardone, C.
|
|
|
28 |
S6 |
p. vi7-vi8
|
artikel
|
| 120 |
EPHA2 receptor is involved in in vivo acquired resistance to anti-epidermal growth factor receptor (EGFR) treatment in metastatic colorectal cancer
|
Martini, G.
|
|
|
28 |
S6 |
p. vi13
|
artikel
|
| 121 |
Eribulin mesylate in advanced breast cancer: retrospective review of a single institution experience
|
Di Cicilia, R.
|
|
|
28 |
S6 |
p. vi41
|
artikel
|
| 122 |
Estimation of 12-weeks life expectancy in patients (pts) with metastatic gastric cancer (mGC) candidated for second-line treatment: the “Gastric Life” nomogram
|
Morano, F.
|
|
|
28 |
S6 |
p. vi46-vi47
|
artikel
|
| 123 |
Estrogen receptor mutation: a new strategy to overcome endocrine resistance
|
Moretti, A.
|
|
|
28 |
S6 |
p. vi32-vi33
|
artikel
|
| 124 |
Evaluating depression in elderly patients with cancer
|
Parrino, S.
|
|
|
28 |
S6 |
p. vi82
|
artikel
|
| 125 |
Evaluation OF psychological aspects of taking care cancer patients: a multicentre study on a sample of caregivers
|
Ratti, M.M.
|
|
|
28 |
S6 |
p. vi83
|
artikel
|
| 126 |
Evaluation of QoL as a predictor of chemotherapy-induced toxicity
|
Mariotti, S.
|
|
|
28 |
S6 |
p. vi83
|
artikel
|
| 127 |
Evaluation of stromal tumour-infiltrating lymphocytes (TILs) in breast cancer by Dynamic contrast–enhanced magnetic resonance (DCE-MR) imaging
|
De Lisa, M.
|
|
|
28 |
S6 |
p. vi26-vi27
|
artikel
|
| 128 |
Evaluation psychological distress in elderly cancer patients
|
Carapezza, L.
|
|
|
28 |
S6 |
p. vi85-vi86
|
artikel
|
| 129 |
Everolimus-exemestane (EE) vs palbociclib-letrozole (PL) or palbociclib-fulvestrant (PF) in the treatment of metastatic HR+, HER2- breast cancer. Indirect comparisons with network meta-analysis for daily clinical practice
|
Stocchi, L.
|
|
|
28 |
S6 |
p. vi37
|
artikel
|
| 130 |
Exploring the nutrition nursing’s care surrounding terminally ill patient. A scoping review
|
Albanesi, B.
|
|
|
28 |
S6 |
p. vi106
|
artikel
|
| 131 |
Expression and clinical-pathological correlations of the androgen receptor (AR) in a series of ER and PgR negative breast cancers undergoing surgery: our center experience
|
Ritorna, A.
|
|
|
28 |
S6 |
p. vi31
|
artikel
|
| 132 |
Family history of pancreatic cancer in BRCA1/2 testing criteria
|
Toss, A.
|
|
|
28 |
S6 |
p. vi46
|
artikel
|
| 133 |
“Feel beautiful to feel alive”
|
Tonnini, C.
|
|
|
28 |
S6 |
p. vi112
|
artikel
|
| 134 |
Fentanyl pectin nasal spray for breakthrough cancer pain treatment: a single center experience
|
Lai, E.
|
|
|
28 |
S6 |
p. vi102-vi103
|
artikel
|
| 135 |
Final analysis of the phase III multicentric Italian study Short-HER: 9 weeks vs 1 year adjuvant trastuzumab for HER2+ early breast cancer
|
Conte, P.
|
|
|
28 |
S6 |
p. vi1
|
artikel
|
| 136 |
Final results from CAMEO-PRO study: complementary and alternative medicine in oncology. physicians inform oncological patients
|
Bozza, C.
|
|
|
28 |
S6 |
p. vi94
|
artikel
|
| 137 |
First-line bevacizumab in combination with weekly paclitaxel for metastatic breast cancer: efficacy and safety results from a routine oncology practice analysis
|
Vannini, A.
|
|
|
28 |
S6 |
p. vi35
|
artikel
|
| 138 |
First-line platinum-based chemotherapy in elderly patients with NSCLC: determinants of therapeutic choice and outcome
|
Pelizzari, G.
|
|
|
28 |
S6 |
p. vi61
|
artikel
|
| 139 |
First line treatment with carboplatin-paclitaxel-bevacizumab in ovarian cancer: retrospective review of a single institute experience
|
Bologna, A.
|
|
|
28 |
S6 |
p. vi71
|
artikel
|
| 140 |
First prospective multicenter Italian study on the impact of the 21-gene recurrence score (RS) in adjuvant clinical decisions for ER+/HER2- early breast cancer (BC) patients
|
Dieci, M.V.
|
|
|
28 |
S6 |
p. vi31
|
artikel
|
| 141 |
Focus on metastatic right-sided colon cancer: the best overall response to the first-line non-EGFR treatment correlates with better overall survival
|
Abbati, F.
|
|
|
28 |
S6 |
p. vi14
|
artikel
|
| 142 |
FOLFOX4/XELOX in stage II–III colon cancer: early survival data of the Italian Three Or Six Colon Adjuvant (TOSCA) trial
|
Zaniboni, A.
|
|
|
28 |
S6 |
p. vi1
|
artikel
|
| 143 |
From the CLEOPATRA study to real life: preliminary results from the G.O.N.O. SUPER trial
|
Garrone, O.
|
|
|
28 |
S6 |
p. vi28-vi29
|
artikel
|
| 144 |
18F-sodium fluoride (18F-NaF) PET/CT scan for the assessment of brain metastases (BMs)
|
Inno, A.
|
|
|
28 |
S6 |
p. vi77
|
artikel
|
| 145 |
Fulvestrant (FUL) as first-line therapy in HR+ve, HER2-ve advanced breast cancer (ABC) patients (pts): when clinical practice comes earlier than clinical trials. Results from the GIM-13 AMBRA study
|
Pronzato, P.
|
|
|
28 |
S6 |
p. vi32
|
artikel
|
| 146 |
Gemcitabine/nabpaclitaxel in elderly patients with metastatic or locally advanced pancreatic adenocarcinoma: a retrospective analysis on the efficacy and safety profile
|
Ventriglia, J.
|
|
|
28 |
S6 |
p. vi51
|
artikel
|
| 147 |
Gender and MGMT methylation in glioblastoma patients: interactions in the PERNO prospective study
|
Franceschi, E.
|
|
|
28 |
S6 |
p. vi75
|
artikel
|
| 148 |
Gene-expression profiles of primary and metastatic lesions in head and neck squamous cell carcinoma
|
Alfieri, S.
|
|
|
28 |
S6 |
p. vi73
|
artikel
|
| 149 |
Genetic counseling for BRCA1/BRCA2 testing
|
Rossi, E.
|
|
|
28 |
S6 |
p. vi79
|
artikel
|
| 150 |
Genetic Factors Associated with Platinum Toxicity: A Preliminary Study
|
De Troia, B.
|
|
|
28 |
S6 |
p. vi95
|
artikel
|
| 151 |
Germline variants and clinical outcomes of high-risk stage II and stage III colon cancer patients treated with oxaliplatin and fluoropyrimidines adjuvant chemotherapy: a pharmacogenetic ancillary study to TOSCA trial
|
Ruzzo, A.
|
|
|
28 |
S6 |
p. vi3-vi4
|
artikel
|
| 152 |
Hair loss prevention by scalp cooling device in early breast cancer patients: the Poliambulanza experience
|
Prochilo, T.
|
|
|
28 |
S6 |
p. vi35
|
artikel
|
| 153 |
HER2 negative metastatic gastric cancer (mGC): a retrospective analysis on the efficacy of doublet or triplet chemotherapy (CT) as a first-line therapy in the clinical practice
|
Petrillo, A.
|
|
|
28 |
S6 |
p. vi51
|
artikel
|
| 154 |
High cumulative anthracycline dose without cardiac toxicity: a study on outlier patients
|
Canale, M.L.
|
|
|
28 |
S6 |
p. vi91
|
artikel
|
| 155 |
Histopathologic response and growth patterns of colorectal cancer liver metastases (CRCLM) in patients treated with triplets plus bevacizumab (bev) or anti-EGFRs
|
Marmorino, F.
|
|
|
28 |
S6 |
p. vi6
|
artikel
|
| 156 |
How can molecular heterogeneity impact on treatment choice in advanced colorectal cancer?
|
De Maglio, G.
|
|
|
28 |
S6 |
p. vi12
|
artikel
|
| 157 |
Hypercoagulable state as marker of occult cancer in healthy blood donors: data from HYPERCAN Prospective Study
|
Gamba, S.
|
|
|
28 |
S6 |
p. vi79-vi80
|
artikel
|
| 158 |
IDH mutant and 1p19q codeleted low grade gliomas: to treat or not to treat?
|
Tosoni, A.
|
|
|
28 |
S6 |
p. vi75
|
artikel
|
| 159 |
“I have a cancer, I am ill, it’s Sunday, my oncologist is not here, I am despairing.” How a telephone call can resolve a great difficulty of cancer patients
|
Orlandi, E.
|
|
|
28 |
S6 |
p. vi85
|
artikel
|
| 160 |
Image and self-esteem: a photo-therapy program to improve body image, increase self-awareness and the expression of emotions in breast cancer patients. A pilot study
|
Marafante, G.
|
|
|
28 |
S6 |
p. vi86
|
artikel
|
| 161 |
Image-guided SIB-IMRT for the treatment of anal cancer patients
|
Franco, P.
|
|
|
28 |
S6 |
p. vi8
|
artikel
|
| 162 |
Immune inflammation indicators as predictors of releaps or new HCC in patients treated with direct-acting antiviral (DAA) for hepatitis C
|
Foschi, F.G.
|
|
|
28 |
S6 |
p. vi48
|
artikel
|
| 163 |
Impact of metabolic syndrome on clinical outcome of castration resistant prostate cancer (CRPC) patients treated with abiraterone and enzalutamide
|
Conteduca, V.
|
|
|
28 |
S6 |
p. vi17
|
artikel
|
| 164 |
Impact of phospho-Akt expression on the clinical outcome and activity of gemcitabine and Akt inhibitors in pancreatic ductal adenocarcinoma
|
Massihnia, D.
|
|
|
28 |
S6 |
p. vi45
|
artikel
|
| 165 |
Implementation of the International Myeloma Working Group reccomendations on renal impairment in multiple myeloma patients in routine clinical practice
|
Torchio, M.
|
|
|
28 |
S6 |
p. vi98
|
artikel
|
| 166 |
Incidence of alcoholism among cancer patients undergoing active treatment
|
Verna, L.
|
|
|
28 |
S6 |
p. vi85
|
artikel
|
| 167 |
Increased frequency of acute reactions to iodinated contrast media after anti-CTLA-4 immunomodulating antibodies in cancer patients
|
Ridolfi, L.
|
|
|
28 |
S6 |
p. vi93
|
artikel
|
| 168 |
Insights from a long-term follow-up evaluation of early breast cancer (BC) outcomes by tumor subtype (TS)
|
Zanardi, E.
|
|
|
28 |
S6 |
p. vi33-vi34
|
artikel
|
| 169 |
Integrating programmed cell death ligand 1 (PD-L1) and neutrophil to lymphocyte ratio (NLR) as predictive panel of response to nivolumab in non-small cell lung cancer (NSCLC)
|
Bennati, C.
|
|
|
28 |
S6 |
p. vi56
|
artikel
|
| 170 |
Integration of Palliative and Oncology Care in patients with lung and other thoracic cancer: referral criteria and clinical care pathways
|
Lo Dico, S.
|
|
|
28 |
S6 |
p. vi89-vi90
|
artikel
|
| 171 |
Intensive mucositis management in head and neck cancer patients treated with concomitant chemo-radiotherapy: the pivotal role of the nurse
|
Cocconi, S.
|
|
|
28 |
S6 |
p. vi107
|
artikel
|
| 172 |
Internet in oncology: a new way to improve communication and information?
|
Di Nunzio, C.
|
|
|
28 |
S6 |
p. vi98
|
artikel
|
| 173 |
Is chemotherapy worthwhile in patients with high-risk, lymph node negative, FIGO stage 1, endometrial cancer?
|
Fontanella, C.
|
|
|
28 |
S6 |
p. vi70
|
artikel
|
| 174 |
ISOLA15: A multicenter study to assess the perception of protective isolation in cancer patients receiving hematopoietic stem cell transplantation
|
Biagioli, V.
|
|
|
28 |
S6 |
p. vi108-vi109
|
artikel
|
| 175 |
Italian translation of a nursing instructor helping the patient to treat oral antineoplastic medicine: the MOATT
|
Gambalunga, F.
|
|
|
28 |
S6 |
p. vi105
|
artikel
|
| 176 |
LibroBluApp: a mobile app to improve cancer care
|
Rapposelli, I.G.
|
|
|
28 |
S6 |
p. vi100
|
artikel
|
| 177 |
Linkage project: specific training of a linguistic-cultural mediator for the management of Chinese cancer patients resident in Italy within healthcare facilities
|
Montone, R.
|
|
|
28 |
S6 |
p. vi83-vi84
|
artikel
|
| 178 |
Locoregional treatments and sites of metastatic involvement in metastatic gastric cancer patients: do they influence survival?
|
Cantini, L.
|
|
|
28 |
S6 |
p. vi49
|
artikel
|
| 179 |
Longer intervals after neoadjuvant therapy in locally advanced rectal cancer: a monocentric experience
|
Murialdo, R.
|
|
|
28 |
S6 |
p. vi6
|
artikel
|
| 180 |
Long-lasting strategy of pain management: the “comitato ospedale senza dolore”
|
Borgonovo, K.F.
|
|
|
28 |
S6 |
p. vi103
|
artikel
|
| 181 |
Long term results of ASTER study, a single Institution phase II trial of sequential chemotherapy (CT) for operable breast cancer (BC)
|
Mariani, G.
|
|
|
28 |
S6 |
p. vi34
|
artikel
|
| 182 |
Maintenance treatment with bevacizumab in metastatic colorectal cancer: intermittent or continuous therapy? A monoinstitutional observational study
|
Cerchiaro, E.
|
|
|
28 |
S6 |
p. vi12
|
artikel
|
| 183 |
Malignant pleural mesothelioma multidisciplinary team unit: experience of one high-volume center in Italy
|
Gianoncelli, L.
|
|
|
28 |
S6 |
p. vi63
|
artikel
|
| 184 |
Management of breakthrough cancer pain in patients with oral mucositis
|
Tolu, S.
|
|
|
28 |
S6 |
p. vi104
|
artikel
|
| 185 |
Management of folinic acid administration in patients with metastatic colo-rectal cancer
|
Romagnoli, E.
|
|
|
28 |
S6 |
p. vi10-vi11
|
artikel
|
| 186 |
Manipulative scar treatment and ostheopatic manipulative treatment for pain, shoulder motion and quality of life in post-mastectomy pain syndrome (PMPS). A randomized clinical trial
|
Figini, D.
|
|
|
28 |
S6 |
p. vi104
|
artikel
|
| 187 |
Massage therapy and quality of life of cancer patient in palliative care: literature review
|
Piazza, M.
|
|
|
28 |
S6 |
p. vi111
|
artikel
|
| 188 |
Medical management of malignant bowel obstruction: our center experience
|
Astara, G.
|
|
|
28 |
S6 |
p. vi15
|
artikel
|
| 189 |
Medication-Related Osteonecrosis of JAW (MR-ONJ) After Bisphosphonates, Denosumab and other Drugs in Advanced Cancer Patients: Recent Experience Data from Rete Oncologica Piemonte – Valle D’aosta (North-Western Italy Cancer Network)
|
Fusco, V.
|
|
|
28 |
S6 |
p. vi90
|
artikel
|
| 190 |
Metastatic melanoma patients treated with Braf and Mek inhibitors: Patterns of progression. An Italian Melanoma Intergroup study
|
Marconcini, R.
|
|
|
28 |
S6 |
p. vi68-vi69
|
artikel
|
| 191 |
Metformin and risk recurrence in resected stage II/III colon cancer (CC) patients (pts): subgroup analysis from the TOSCA trial
|
Di Bartolomeo, M.
|
|
|
28 |
S6 |
p. vi9
|
artikel
|
| 192 |
Metformin effects on clinical outcome in advanced HCC patients receiving sorafenib: validation study
|
Faloppi, L.
|
|
|
28 |
S6 |
p. vi44
|
artikel
|
| 193 |
Metronomic chemotherapy (mCHT) in HER2-ve advanced breast cancer (ABC) patients (pts): old drugs, new results. The multicenter VICTOR-6 study
|
Cazzaniga, M.
|
|
|
28 |
S6 |
p. vi29
|
artikel
|
| 194 |
Micetrin to prevent chemotherapy-induced nausea and fatigue in adjuvant treatment of breast cancer
|
Galanti, D.
|
|
|
28 |
S6 |
p. vi92
|
artikel
|
| 195 |
Molecular characterization and pharmacological profile of myxofibrosarcoma primary cultures
|
De Vita, A.
|
|
|
28 |
S6 |
p. vi66
|
artikel
|
| 196 |
Molecular profile characterization and impact on clinical outcome in metastatic NSCLC patients enrolled in MOSCATO 01 trial
|
Buzzatti, G.
|
|
|
28 |
S6 |
p. vi55
|
artikel
|
| 197 |
Monitoring metastatic breast cancer (M-MBC) during treatment: a GIM (Gruppo Italiano Mammella) survey
|
Bonotto, M.
|
|
|
28 |
S6 |
p. vi30
|
artikel
|
| 198 |
MTHFR, TSER and DPYD gene mutation is associated with toxicity and response in pre-operative chemo-radiotherapy for local advanced rectal cancer
|
De Giorgi, D.
|
|
|
28 |
S6 |
p. vi14-vi15
|
artikel
|
| 199 |
Multidisciplinary approach and nutritional impact on the patient with pancreatic cancer
|
Durelli, P.
|
|
|
28 |
S6 |
p. vi49-vi50
|
artikel
|
| 200 |
Multiple treatment lines and prognosis for metastatic colorectal (mCRC) patients (pts)
|
Rosanova, M.
|
|
|
28 |
S6 |
p. vi8-vi9
|
artikel
|
| 201 |
Music and its influence on affectivity and relationships in oncologic and hematologic patients
|
Tirelli, E.
|
|
|
28 |
S6 |
p. vi85
|
artikel
|
| 202 |
Music intervention during chemotherapy infusion reduces anxiety in oncological patients
|
Massimiliani, V.
|
|
|
28 |
S6 |
p. vi82
|
artikel
|
| 203 |
Mutational status and metastatic patteRn in a cohort Of ADvanced colorectal cancer patients: the ROAD study
|
Ongaro, E.
|
|
|
28 |
S6 |
p. vi10
|
artikel
|
| 204 |
Nab-paclitaxel in clinical practice: data from the MANTEL study
|
Vanella, P.
|
|
|
28 |
S6 |
p. vi35
|
artikel
|
| 205 |
Nab-paclitaxel (Nab-P) in HER2-ve advanced breast cancer (ABC) patients (pts): focus on luminal cancers. Results from GIM13 - AMBRA study
|
Mustacchi, G.
|
|
|
28 |
S6 |
p. vi34
|
artikel
|
| 206 |
Nab-paclitaxel plus gemcitabine in the treatment of metastatic pancreatic cancer: our experience
|
Mare, M.
|
|
|
28 |
S6 |
p. vi52
|
artikel
|
| 207 |
Narrative Medicine: from words ..... to actions
|
Reggiani, R.
|
|
|
28 |
S6 |
p. vi111
|
artikel
|
| 208 |
Narrative review of quality of life in survivors of colorectal cancer
|
Laura, S.
|
|
|
28 |
S6 |
p. vi109
|
artikel
|
| 209 |
Neutrophil-to-lymphocyte and lymphocyte-to-monocyte ratios in breast cancer
|
Gerratana, L.
|
|
|
28 |
S6 |
p. vi27
|
artikel
|
| 210 |
Neutrophil-to-lymphocyte ratio in metastatic breast cancer patients: relationship with tumor characteristics and survival
|
Bartoletti, M.
|
|
|
28 |
S6 |
p. vi33
|
artikel
|
| 211 |
New rules for clinical trials: who will play the game?
|
Monti, M.
|
|
|
28 |
S6 |
p. vi93-vi94
|
artikel
|
| 212 |
Nivolumab in non-small cell lung cancer: is there an upper age limit?
|
De Pietro, L.
|
|
|
28 |
S6 |
p. vi60
|
artikel
|
| 213 |
Nutritional counseling
|
Pacetti, P.
|
|
|
28 |
S6 |
p. vi99-vi100
|
artikel
|
| 214 |
Nutritional Counseling with or without Systematic Use of Oral Nutritional Supplements in Head and Neck Cancer Patients Undergoing Radiotherapy
|
Caccialanza, R.
|
|
|
28 |
S6 |
p. vi89
|
artikel
|
| 215 |
Nutritional status in elderly cancer patients: Prospective observational study
|
Gagliardi, C.
|
|
|
28 |
S6 |
p. vi107
|
artikel
|
| 216 |
Observational case-control study about the adherence to the Mediterranean diet in elderly oncological patients in Salento
|
Silvana, L.
|
|
|
28 |
S6 |
p. vi80
|
artikel
|
| 217 |
Observational study on dietary habits and quality of life in patients with colorectal cancer
|
D'Ottavio, A.
|
|
|
28 |
S6 |
p. vi106
|
artikel
|
| 218 |
Observational study on the effectiveness of the Dragon Boat in reducing the risk of incidence of lymphedema in women with breast cancer
|
Molinaro, S.
|
|
|
28 |
S6 |
p. vi105
|
artikel
|
| 219 |
Occurrence of ultrasound-detected symptomatic and asymptomatic central vein catheter-related thrombosis in pediatric oncology patients
|
Gandini, L.
|
|
|
28 |
S6 |
p. vi80
|
artikel
|
| 220 |
Odynophagia and dysphagia,: clinical experiences and cancer pain integrated management
|
Parascandolo, I.
|
|
|
28 |
S6 |
p. vi104
|
artikel
|
| 221 |
Oncogeriatric assessment of older patients with cancer in the ASL Cuneo 2
|
Marenco, D.
|
|
|
28 |
S6 |
p. vi100
|
artikel
|
| 222 |
Optimization of the combination of bevacizumab with FOLFOX/OXXEL in patients with metastatic colorectal cancer (mCRC): the multicentre, randomized phase 3 study OBELICS
|
Avallone, A.
|
|
|
28 |
S6 |
p. vi5
|
artikel
|
| 223 |
Oral etoposide in heavily pretreated metastatic breast cancer: a retrospective analysis of efficacy and safety
|
Giannone, G.
|
|
|
28 |
S6 |
p. vi39
|
artikel
|
| 224 |
Osteonecrosis of jaw (ONJ) after antiresorptive treatment (bisphosphonates, denosumab) of cancer-treatment induced bone loss (CTIBL): a negligible risk?
|
Gambino, A.
|
|
|
28 |
S6 |
p. vi96
|
artikel
|
| 225 |
Outcome and prognostic factors after resection of liver metastases in patients with colorectal cancer
|
Baldessari, C.
|
|
|
28 |
S6 |
p. vi13-vi14
|
artikel
|
| 226 |
Overall survival (OS) of selected patients (Pts) with non-small cell lung cancer (NSCLC) receiving nivolumab beyond progression
|
Genova, C.
|
|
|
28 |
S6 |
p. vi61
|
artikel
|
| 227 |
Pancreatic cancer: sharing a nutrition education project with the patients and their care givers
|
Satolli, M.A.
|
|
|
28 |
S6 |
p. vi51-vi52
|
artikel
|
| 228 |
Partial splenic embolization in chemotherapy-induced thrombocytopenia: a retrospective analysis with long term follow up
|
Procaccio, L.
|
|
|
28 |
S6 |
p. vi15
|
artikel
|
| 229 |
Pathogenetic mutations in BRCA related triple negative breast cancer
|
Bini, F.
|
|
|
28 |
S6 |
p. vi34-vi35
|
artikel
|
| 230 |
Patient (pt) characteristics and treatment patterns in the radium (Ra)-223 REASSURE observational study
|
Baldari, S.
|
|
|
28 |
S6 |
p. vi22-vi23
|
artikel
|
| 231 |
Patient relationship training in an integrated perspective: guidelines for psychological intervention
|
Verusio, C.
|
|
|
28 |
S6 |
p. vi88
|
artikel
|
| 232 |
PerTe: efficacy and safety of pertuzumab in “real life setting” for the neoadjuvant treatment of HER2-positive breast cancer patients
|
Cianniello, D.
|
|
|
28 |
S6 |
p. vi36
|
artikel
|
| 233 |
Phase II study of the safety and efficacy of oral capecitabine in patients with platinum-pretreated advanced or recurrent cervical carcinoma
|
Lepori, S.
|
|
|
28 |
S6 |
p. vi70
|
artikel
|
| 234 |
Phase 3 randomized study of adjuvant anastrozole (A), exemestane (E) or letrozole (L) with or without tamoxifen (T) in postmenopausal women with hormone-responsive (HR) breast cancer. The FATA-GIM3 trial
|
De Placido, S.
|
|
|
28 |
S6 |
p. vi1
|
artikel
|
| 235 |
Photography as a therapeutic tool to re-elaborate “cancer” experience
|
Franchina, V.
|
|
|
28 |
S6 |
p. vi87-vi88
|
artikel
|
| 236 |
Plasticity of PD-L1 expression between nodal metastases and primary tumors in p16 negative squamous cell carcinoma of the oral cavity
|
Patriarca, C.
|
|
|
28 |
S6 |
p. vi73-vi74
|
artikel
|
| 237 |
Post-survey data about “I do not smoke it”, smoking prevention campaign addressed to schools
|
Rapetti, S.G.
|
|
|
28 |
S6 |
p. vi79
|
artikel
|
| 238 |
Potential contribution of the study nurse to colorectal cancer (CRC) translational research
|
Rigotto, I.
|
|
|
28 |
S6 |
p. vi110
|
artikel
|
| 239 |
Potential miRNAs involved in molecular pathways mediating the anticancer effects of short term starvation in breast cancer cells treated with doxorubicin
|
Fanale, D.
|
|
|
28 |
S6 |
p. vi38
|
artikel
|
| 240 |
Potential therapeutic combination of beta-blockers and trabectedin in metastatic soft tissue sarcoma and ovarian cancer
|
Porcelli, L.
|
|
|
28 |
S6 |
p. vi66-vi67
|
artikel
|
| 241 |
Prediction of overall survival after 3 months of treatment using the NLR-over-the-time curve in pancreatic cancer patients
|
Morelli, C.
|
|
|
28 |
S6 |
p. vi50
|
artikel
|
| 242 |
Preliminary data for assessing the impact of psychological stress on the development of primitive tumors or relapses of disease
|
Dessì, A.
|
|
|
28 |
S6 |
p. vi87
|
artikel
|
| 243 |
Prevalence of KRAS, NRAS and BRAF mutations detected by massive parallel sequencing and differential clinical outcome in metastatic colorectal cancer (MCRC) patients (pts) treated with first line FIr-B/FOx adding bevacizumab (BEV) to triplet chemotherapy
|
Bruera, G.
|
|
|
28 |
S6 |
p. vi14
|
artikel
|
| 244 |
Preventive dose reduction of capecitabine in elderly population
|
Guidi, A.
|
|
|
28 |
S6 |
p. vi98
|
artikel
|
| 245 |
Primary tumor site (pTS) as a key factor in adjuvant treatment decision in resected N+ colorectal cancer patients
|
Giampieri, R.
|
|
|
28 |
S6 |
p. vi11
|
artikel
|
| 246 |
Procedural pain: acknowledgement of the issue by palliative care professionals
|
Nazzicone, G.
|
|
|
28 |
S6 |
p. vi104
|
artikel
|
| 247 |
Prognostic factors associated with survival and recurrence in resectable gastroesophageal cancer: retrospective analysis of 338 patients operated at the Hospital of Cremona in ten years' time
|
Ghidini, M.
|
|
|
28 |
S6 |
p. vi50
|
artikel
|
| 248 |
Prognostic factors in unresectable biliary tract cancer: a GICO (Gruppo Italiano COlangiocarcinoma) retrospective analysis
|
Leone, F.
|
|
|
28 |
S6 |
p. vi48
|
artikel
|
| 249 |
Prognostic impact of CA15-3 pre-treatment levels in ovarian cancer patients
|
Maccaroni, E.
|
|
|
28 |
S6 |
p. vi71-vi72
|
artikel
|
| 250 |
Prognostic impact of hyponatremia in patients affected by advanced non-small cell lung cancer (NSCLC) with bone metastases (BMs)
|
Rinaldi, S.
|
|
|
28 |
S6 |
p. vi59
|
artikel
|
| 251 |
Prognostic impact of nutritional support in patients affected by locally advanced or metastatic pancreatic cancer (PC) undergone chemotherapy
|
Trestini, I.
|
|
|
28 |
S6 |
p. vi47
|
artikel
|
| 252 |
Prognostic relevance of VEGF, VEGFR, IGF and IGFR immunohistochemical expression in gastroenteropancreatic neuroendocrine tumors
|
Torniai, M.
|
|
|
28 |
S6 |
p. vi78
|
artikel
|
| 253 |
Prognostic role of aspartate aminotransferase-lymphocyte ratio index (ALRI) in patients with metastatic colorectal cancer: results from the ITACa trial
|
Passardi, A.
|
|
|
28 |
S6 |
p. vi13
|
artikel
|
| 254 |
Prognostic role of disease extent and lymphocyte-monocyte ratio in advanced melanoma
|
Iacono, D.
|
|
|
28 |
S6 |
p. vi68
|
artikel
|
| 255 |
Prognostic value of lymph node ratio in early breast cancer: a restrospective single institution analysis of clinical-pathological characteristics and outcomes
|
Diodati, L.
|
|
|
28 |
S6 |
p. vi37-vi38
|
artikel
|
| 256 |
Prognostic value of systemic inflammatory biomarkers in patients with mCRPC treated with Abiraterone in pre-docetaxel setting
|
Ratta, R.
|
|
|
28 |
S6 |
p. vi20
|
artikel
|
| 257 |
Prognostic value of tumor-infiltrating lymphocytes in small HER2-positive breast cancer
|
Criscitiello, C.
|
|
|
28 |
S6 |
p. vi32
|
artikel
|
| 258 |
Programmed death ligand 1 (PD-L1) expression status as prognostic factor in early stage non-small cell lung cancer (NSCLC)
|
D'Arcangelo, M.
|
|
|
28 |
S6 |
p. vi59
|
artikel
|
| 259 |
Prophylactic use of antiemetics for prevention of opioid-induced nausea and vomiting: a web based online survey among Italian experts on supportive care in cancer
|
Giusti, R.
|
|
|
28 |
S6 |
p. vi103
|
artikel
|
| 260 |
Prospective generation of PDTX (patient derived tumor xenografts) and molecular profiling of NSCLC (non small cell lung cancer)
|
Mele, T.
|
|
|
28 |
S6 |
p. vi58
|
artikel
|
| 261 |
Prospective qualitative study on the emotional experience of the patient undergoing radical prostatectomy
|
Iacorossi, L.
|
|
|
28 |
S6 |
p. vi107-vi108
|
artikel
|
| 262 |
Prospective translational study investigating circulating predictors of outcome to first-line pazopanib in patients with metastatic renal cell carcinoma (mRCC)
|
Grassi, P.
|
|
|
28 |
S6 |
p. vi18
|
artikel
|
| 263 |
Psychological resources and strengths in adults living with lung cancer. A pilot study
|
Palazzolo, G.
|
|
|
28 |
S6 |
p. vi84
|
artikel
|
| 264 |
Quality of end of life care in patients with pancreatic cancer receiving systematic versus on-demand early palliative care at diagnosis: a secondary outcome analysis from a randomized controlled trial
|
Brunelli, C.
|
|
|
28 |
S6 |
p. vi89
|
artikel
|
| 265 |
223Ra-chloride therapy: the first multidisciplinary and multicenter Italian study
|
Farnesi, A.
|
|
|
28 |
S6 |
p. vi23
|
artikel
|
| 266 |
Radically resected stage III colorectal cancer: sidedness and prognosis
|
Massucci, M.
|
|
|
28 |
S6 |
p. vi11
|
artikel
|
| 267 |
Radium-223 in metastatic castration-resistant prostate cancer (mCRPC): efficacy and safety in real-life experience
|
Rebuzzi, S.E.
|
|
|
28 |
S6 |
p. vi23-vi24
|
artikel
|
| 268 |
Radium-223 with concomitant bone-targeting agents in metastatic castration-resistant prostate cancer (CRPC) patients treated in an international early access program (EAP)
|
Paganelli, G.
|
|
|
28 |
S6 |
p. vi18-vi19
|
artikel
|
| 269 |
Randomized phase 1b/3 study of erlotinib plus ramucirumab in first-line EGFR mut + stage IV NSCLC: phase 1b safety results
|
Nakagawa, K.
|
|
|
28 |
S6 |
p. vi56
|
artikel
|
| 270 |
Randomized phase 2 trial of nab-paclitaxel plus gemcitabine, ± capecitabine, cisplatin (paxg regimen) in metastatic pancreatic adenocarcinoma
|
Zanon, S.
|
|
|
28 |
S6 |
p. vi44-vi45
|
artikel
|
| 271 |
Randomized phase 2 trial of peri- or post-operative chemotherapy in resectable pancreatic adenocarcinoma
|
Reni, M.
|
|
|
28 |
S6 |
p. vi44
|
artikel
|
| 272 |
Rechallenge in GIST progressing to imatinib, sunitinib and regorafenib: An Italian survey
|
Vincenzi, B.
|
|
|
28 |
S6 |
p. vi66
|
artikel
|
| 273 |
Rechallenge with cetuximab (cet) + irinotecan (iri) in 3rd-line in RAS and BRAF wt metastatic colorectal cancer (mCRC) patients (pts) with acquired resistance to 1st-line cet + iri: the phase II CRICKET study by GONO
|
Santini, D.
|
|
|
28 |
S6 |
p. vi9
|
artikel
|
| 274 |
Relevance of immunohistochemical (IHC) surrogate reclassification of pT1 breast cancer in luminal-like subtypes: a 15-years long-term observational retrospective study
|
Emiliani, A.
|
|
|
28 |
S6 |
p. vi28
|
artikel
|
| 275 |
Response rate by molecular subtypes and p53 expression in neoadjuvant therapy for breast cancer with TAC regimen: a single-centre experience
|
Marcon, I.
|
|
|
28 |
S6 |
p. vi38
|
artikel
|
| 276 |
Results of an integrated multi-platforms analysis in squamous cell lung carcinoma (SqCLC) revealed PI3K/RICTOR-mTORC2 axis as a potential prognostic biomarker and druggable target
|
Pilotto, S.
|
|
|
28 |
S6 |
p. vi57
|
artikel
|
| 277 |
RET rearrangements define an uncommon molecular subtype of metastatic colorectal cancer (mCRC)
|
Pietrantonio, F.
|
|
|
28 |
S6 |
p. vi6-vi7
|
artikel
|
| 278 |
Retrospective analysis of 77 patients with ovarian cancer undergoing genetic testing for BRCA1 and BRCA2 mutations
|
Tavella, K.
|
|
|
28 |
S6 |
p. vi71
|
artikel
|
| 279 |
Retrospective analysis of the therapeutic efficacy of platinum/etoposide schedules in the treatment of advanced poor differentiated neuroendocrine carcinomas of the lung
|
Chillari, F.
|
|
|
28 |
S6 |
p. vi78
|
artikel
|
| 280 |
Risk and protective factors for the construction of prenatal attachment in women with oncological diagnosis during pregnancy: an exploratory observational study
|
Bonassi, L.
|
|
|
28 |
S6 |
p. vi82-vi83
|
artikel
|
| 281 |
Role and competence of oncology nurse: a narrative review
|
Ricci, F.
|
|
|
28 |
S6 |
p. vi108
|
artikel
|
| 282 |
Role of Anaplus HP in prevention of chemotherapy-induced peripheral neuropathy (CIPN) in patients affected by breast cancer treated with taxane-based adjuvant chemotherapy
|
La Vecchia, M.
|
|
|
28 |
S6 |
p. vi92
|
artikel
|
| 283 |
Role of DCE-MR imaging of the breast in predicting breast cancer subtypes: where are we going?
|
Bastianelli, L.
|
|
|
28 |
S6 |
p. vi33
|
artikel
|
| 284 |
Role of inflammation parameters in locally advanced breast cancer: the debate is still open
|
Merloni, F.
|
|
|
28 |
S6 |
p. vi37
|
artikel
|
| 285 |
Role of Theatre as Psychological Support in Cancer Patient
|
Barzelloni, M.L.
|
|
|
28 |
S6 |
p. vi84-vi85
|
artikel
|
| 286 |
Safety and Efficacy of Abiraterone Acetate in Patients (pts) aged 75 or more with Metastatic Castration Resistant Prostate Cancer (mCRPC) in Both Pre-chemotherapy and Post-chemotherapy Settings: The Real Life Experience of Our Institution
|
Sirotovà, Z.
|
|
|
28 |
S6 |
p. vi22
|
artikel
|
| 287 |
Safety and efficacy of cabozantinib for metastatic renal cell carcinoma (mRCC): real world data from an Italian Expanded Access Program (EAP)
|
Michele, P.
|
|
|
28 |
S6 |
p. vi18
|
artikel
|
| 288 |
Safety and efficacy of non-pegylated liposomal doxorubicin (NPLD) in HER2 negative metastatic breast cancer (mBC) patients (PTS) as second-line (2L) and beyond: a restrospective single institution analysis
|
De Angelis, C.
|
|
|
28 |
S6 |
p. vi42
|
artikel
|
| 289 |
Safety and efficacy of the treatment with Nab-paclitaxel in mEtastatic bREast cancer In elDerly patiEnts: NEREIDE study
|
Adamo, V.
|
|
|
28 |
S6 |
p. vi40
|
artikel
|
| 290 |
Safety and metabolic effects of the fasting mimicking diet in cancer patients
|
Vernieri, C.
|
|
|
28 |
S6 |
p. vi96
|
artikel
|
| 291 |
Scalp cooling: a real opportunity to prevent alopecia in breast cancer women undergoing chemotherapy?
|
Martella, L.R.
|
|
|
28 |
S6 |
p. vi39
|
artikel
|
| 292 |
Screening of distress in hospitalized patients: the experience of medical oncology department
|
Tinelli, G.
|
|
|
28 |
S6 |
p. vi86-vi87
|
artikel
|
| 293 |
Second-line treatment efficacy in elderly vs. non-elderly advanced gastric cancer patients: an Italian multicentre real-world study
|
Fanotto, V.
|
|
|
28 |
S6 |
p. vi45
|
artikel
|
| 294 |
Sharing long term follow-up of breast cancer survivors with family physician: a province of Lecco experience
|
Villa, F.
|
|
|
28 |
S6 |
p. vi79
|
artikel
|
| 295 |
Shiatsu in oncology: a treatment of healing processes’ activation. Observational study
|
Geremia, S.
|
|
|
28 |
S6 |
p. vi110-vi111
|
artikel
|
| 296 |
Sidedness influences prognosis in colon cancer patients receiving an adjuvant therapy. A GISCAD analysis from three randomized trials including 5234 patients
|
Gelsomino, F.
|
|
|
28 |
S6 |
p. vi5
|
artikel
|
| 297 |
Simultaneous Care clinic: a three-year monoinstitutional experience
|
Stragliotto, S.
|
|
|
28 |
S6 |
p. vi89
|
artikel
|
| 298 |
Simultaneous Home Care project for frail advanced cancer patients: a model of integration between no profit and Public Health System
|
Chini, C.
|
|
|
28 |
S6 |
p. vi90
|
artikel
|
| 299 |
Size does matter: comparison of activity between anti-EGFR and anti-VEGF based-treatment in RAS wild type colorectal cancer patients, stratified by size of metastatic involvement
|
Del Prete, M.
|
|
|
28 |
S6 |
p. vi7
|
artikel
|
| 300 |
Skin rash and response to cetuximab treatment: a retrospective single-center analysis
|
Cau, M.C.
|
|
|
28 |
S6 |
p. vi74
|
artikel
|
| 301 |
Sleep and hematopoietic stem cell transplantation: a pilot study with sleep questionnaire in the intensive care unit
|
Brusaferri, D.
|
|
|
28 |
S6 |
p. vi109
|
artikel
|
| 302 |
Small bowel adenocarcinoma (SBA) is a rare and heterogeneous disease: results of a retrospective analysis
|
Andrikou, K.
|
|
|
28 |
S6 |
p. vi50-vi51
|
artikel
|
| 303 |
Small luminal-like breast cancer: determinants of adjuvant chemotherapy use
|
Bettini, A.
|
|
|
28 |
S6 |
p. vi33
|
artikel
|
| 304 |
Start (active surveillance or radical treatment for newly diagnosed patients with a localized, low risk, prostate cancer): an epidemiological study of the Oncology Network of Piemonte and Valle d’Aosta. Update 2017
|
Galassi, C.
|
|
|
28 |
S6 |
p. vi20-vi21
|
artikel
|
| 305 |
Strategy of monitoring metastatic breast cancer (M-MBC) in clinical practice: more or less intensive?
|
Vitale, M.G.
|
|
|
28 |
S6 |
p. vi30
|
artikel
|
| 306 |
Stromal peritumoral and intratumoral infiltrating lymphocytes: how immunity influences prognosis in triple negative breast cancer
|
Della Mora, A.
|
|
|
28 |
S6 |
p. vi31-vi32
|
artikel
|
| 307 |
Subgroup analysis of patients (Pts) refractory to first-line (1L) chemotherapy from REVEL, a randomized phase 3 study of docetaxel (DOC) with ramucirumab (RAM) or placebo (PBO) for second-line (2L) treatment of stage IV non-small-cell lung cancer (NSCLC)
|
Reck, M.
|
|
|
28 |
S6 |
p. vi54-vi55
|
artikel
|
| 308 |
Subsite-dependent prognostic impact of age in patients with nasopharyngeal and oropharyngeal cancer
|
Granata, R.
|
|
|
28 |
S6 |
p. vi74
|
artikel
|
| 309 |
Sunitinb, hypertension and renal function: a monocentric experience
|
Dognini, G.P.
|
|
|
28 |
S6 |
p. vi91
|
artikel
|
| 310 |
Surgery and the elderly: when an apparent overtreatment becomes safe and effective
|
Mordenti, P.
|
|
|
28 |
S6 |
p. vi100
|
artikel
|
| 311 |
Surgery in multimodal management in non-metastatic small cell lung cancer: a retrospective monocentric series
|
Di Liso, E.
|
|
|
28 |
S6 |
p. vi61
|
artikel
|
| 312 |
Survival analysis of KRAS, NRAS, BRAF, PIK3CA wild type (wt) metastatic colorectal cancer (mCRC) patients (pts) treated with FOLFIRI plus cetuximab in the CAPRI- GOIM trial
|
Ciardiello, F.
|
|
|
28 |
S6 |
p. vi5
|
artikel
|
| 313 |
Survival of metastatic colorectal cancer patients at Candiolo Cancer Institute
|
Fenocchio, E.
|
|
|
28 |
S6 |
p. vi11
|
artikel
|
| 314 |
Suspicious for recurrent low and high grade glioma and indeterminate MRI: the role of 18F-DOPA PET/CT
|
Cuppari, L.
|
|
|
28 |
S6 |
p. vi76-vi77
|
artikel
|
| 315 |
Table of Contents
|
|
|
|
28 |
S6 |
p. iv
|
artikel
|
| 316 |
Taxane-rechallenge in HER2-positive breast cancer patients who develop an oligo-progression during pertuzumab-trastuzumab maintenance therapy
|
Cito, P.
|
|
|
28 |
S6 |
p. vi43
|
artikel
|
| 317 |
The acquired resistance to the combination of the anti-EGFR cetuximab and the MEK-inhibitor refametinib in KRAS mutated colorectal cancer cell lines depends on PI3K-signalling
|
Vitiello, P.P.
|
|
|
28 |
S6 |
p. vi14
|
artikel
|
| 318 |
The APE1/NPM1 axis in triple negative breast cancer: prognostic and therapeutic implications
|
Malfatti, M.C.
|
|
|
28 |
S6 |
p. vi36
|
artikel
|
| 319 |
The close link between anxiety and cluster symptoms in lung cancer patients during first-line chemotherapy: further data from a dedicated WALCE (Women Against Lung Cancer in Europe) survey
|
Carnio, S.
|
|
|
28 |
S6 |
p. vi58
|
artikel
|
| 320 |
The continuing training program of oncology network of Piemonte and Valle d'Aosta: a model for improving the management of oncologic patients
|
Viale, M.
|
|
|
28 |
S6 |
p. vi97
|
artikel
|
| 321 |
The effect of loneliness on cancer mortality
|
D'Ippolito, S.
|
|
|
28 |
S6 |
p. vi82
|
artikel
|
| 322 |
The effects of LIPUS on ctDNA release in the medium of NSCLC cell lines
|
Perez, A.
|
|
|
28 |
S6 |
p. vi62
|
artikel
|
| 323 |
The ENDOPREDICT® molecular test for breast cancer prognosis: clinical-pathological correlations and therapeutic implications on a selected cohort of patients
|
Castellano, I.
|
|
|
28 |
S6 |
p. vi36-vi37
|
artikel
|
| 324 |
The evolution of palliative care from the oncology patient to the chronic illness
|
Rampello, G.
|
|
|
28 |
S6 |
p. vi98-vi99
|
artikel
|
| 325 |
The follow-up and lifestyle (FUCSAM project). Oncology Network of Piemonte and Valle d'Aosta: update 2017
|
Mistrangelo, M.
|
|
|
28 |
S6 |
p. vi80
|
artikel
|
| 326 |
The HERBA trial: a retrospective study on patients (pts) with HER2-positive (HER2+ve) breast cancer (BC) and brain metastases (BMs)
|
Gori, S.
|
|
|
28 |
S6 |
p. vi29-vi30
|
artikel
|
| 327 |
The impact of chemotherapy-related leukopenia on survival outcomes in locally advanced cervical cancer
|
Signorelli, M.
|
|
|
28 |
S6 |
p. vi70
|
artikel
|
| 328 |
The impact of social factors on oncology: The experience of the Reggio Emilia Clinical Cancer Center
|
Larocca, M.
|
|
|
28 |
S6 |
p. vi96
|
artikel
|
| 329 |
The predictive role of toxicity induced by chemotherapy: systematic review on relationship between toxicity and effectiveness
|
Falcone, G.
|
|
|
28 |
S6 |
p. vi106
|
artikel
|
| 330 |
The pre-emptive screening of multiple polymorphisms in gene-encoding dihydropyrimidine dehydrogenase (DPD) improve prevention of toxicity on patients candidate for fluoropyrimidine based-chemotherapy. An experience of the Reggio Emilia Cancer Center
|
Iachetta, F.
|
|
|
28 |
S6 |
p. vi94
|
artikel
|
| 331 |
The Pregnancy and Fertility (PREFER) study: a prospective cohort study on fertility-preserving (FP) strategies in young early breast cancer (EBC) patients (pts)
|
Dellepiane, C.
|
|
|
28 |
S6 |
p. vi26
|
artikel
|
| 332 |
The prognostic impact of sidedness across all stages during the last 20 years: the “Modena Cancer Registry” experience
|
Spallanzani, A.
|
|
|
28 |
S6 |
p. vi10
|
artikel
|
| 333 |
The regorafenib issue: focus on efficacy and safety in pre-treated metastatic colorectal cancer from a real world experience
|
Daniel, F.
|
|
|
28 |
S6 |
p. vi15-vi16
|
artikel
|
| 334 |
The role of clinical and molecular characteristics in low grade gliomas
|
Mura, A.
|
|
|
28 |
S6 |
p. vi75-vi76
|
artikel
|
| 335 |
The role of primary tumour sidedness, EGFR gene copy number and EGFR promoter methylation in RAS/BRAF wild type colorectal cancer patients receiving irinotecan/cetuximab
|
Puzzoni, M.
|
|
|
28 |
S6 |
p. vi9-vi10
|
artikel
|
| 336 |
The role of ribociclib in hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) early breast cancer: the EarLEE adjuvant clinical trials program
|
De Laurentiis, M.
|
|
|
28 |
S6 |
p. vi37
|
artikel
|
| 337 |
The role of the clinical risk group classification system in the management of oncologic patients in need of high complexity of care. A pilot study in the local health unit “USL Umbria 2”
|
Marzulli, T.
|
|
|
28 |
S6 |
p. vi95
|
artikel
|
| 338 |
The role of treatments in IDH mutant molecular astrocytomas
|
Minichillo, S.
|
|
|
28 |
S6 |
p. vi76
|
artikel
|
| 339 |
The tailored nutritional counseling in early cancer patients
|
Pellegrino, R.
|
|
|
28 |
S6 |
p. vi90-vi91
|
artikel
|
| 340 |
The thermometer of distress in oncology
|
Monfredo, M.
|
|
|
28 |
S6 |
p. vi84
|
artikel
|
| 341 |
The TRITON clinical trial programme: evaluation of the PARP inhibitor rucaparib in patients with metastatic castration-resistant prostate cancer (mCRPC) associated with homologous recombination deficiency (HRD)
|
Cora, N.S.
|
|
|
28 |
S6 |
p. vi23
|
artikel
|
| 342 |
The value of trabectedin in the treatment of soft tissue sarcoma: a monoinstitutional retrospective real-life study
|
Turano, S.
|
|
|
28 |
S6 |
p. vi67
|
artikel
|
| 343 |
Three-monthly dynamic evaluation of CEA and CA15-3 and 18-FDG PET vs usual practice in the follow-up of early breast cancer patients: a prospective, multicenter, randomized trial (KRONOS – Patient-Oriented New Surveillance-Study Italy)
|
Barbieri, E.
|
|
|
28 |
S6 |
p. vi81
|
artikel
|
| 344 |
Thrombin generation for prediction of early cancer recurrence in breast cancer patients undergoing post-surgical adjuvant therapy: data from the prospective HYPERCAN study
|
Giaccherini, C.
|
|
|
28 |
S6 |
p. vi93
|
artikel
|
| 345 |
Thrombin generation (TG) and D-dimer levels for the identification of cancer patients at higher VTE risk enrolled in the HYPERCAN study
|
Verzeroli, C.
|
|
|
28 |
S6 |
p. vi93
|
artikel
|
| 346 |
Thymic epithelial tumors (TETs) and additional tumors: a single Centre experience
|
Paolucci, V.
|
|
|
28 |
S6 |
p. vi62
|
artikel
|
| 347 |
Time to surgery after neoadjuvant chemotherapy for early breast cancer
|
Cinausero, M.
|
|
|
28 |
S6 |
p. vi29
|
artikel
|
| 348 |
Transarterial radioembolization versus chemoembolization for hepatocarcinoma patients: a meta-analysis of randomized trial
|
Valgiusti, M.
|
|
|
28 |
S6 |
p. vi49
|
artikel
|
| 349 |
Treatment and outcome for small bowel adenocarcinoma (SBA): a real life experience of two Italian centres
|
Occhipinti, M.
|
|
|
28 |
S6 |
p. vi50
|
artikel
|
| 350 |
Trends in the choice of first line treatment for hormone - responsive (HR+), human epidermal growth factor receptor - 2 negative (HER2-) metastatic breast cancer (MBC) patients (pts): results of a multicentric Italian observational study
|
D' Alonzo, A.
|
|
|
28 |
S6 |
p. vi25
|
artikel
|
| 351 |
Unmet needs in Head and Neck (H&N) cancer patients: unmet needs, emotional disorders and pain
|
Airoldi, M.
|
|
|
28 |
S6 |
p. vi83
|
artikel
|
| 352 |
Updated report of an observational clinical registry (REGCLIN-MM) on malignant pleural mesothelioma (MPM)
|
Grosso, F.
|
|
|
28 |
S6 |
p. vi59
|
artikel
|
| 353 |
Updated results from MONALEESA-2, a phase 3 trial of first-line ribociclib + letrozole in hormone receptor-positive (HR+), HER2-negative (HER2–) advanced breast cancer (ABC)
|
Spazzapan, S.
|
|
|
28 |
S6 |
p. vi28
|
artikel
|
| 354 |
Use of scalp-cooling device to prevent alopecia for breast cancer patients receiving chemotherapy: a single-Institution prospective study
|
Giarratano, T.
|
|
|
28 |
S6 |
p. vi39
|
artikel
|
| 355 |
Very elderly patients and lung cancer in a tertiary care center: a real life experience
|
Ponzetti, A.
|
|
|
28 |
S6 |
p. vi64
|
artikel
|
| 356 |
We are all Jews of somebody: migration and genetic. The story of Jewish settlements in Italian Salento
|
Orlando, L.
|
|
|
28 |
S6 |
p. vi35-vi36
|
artikel
|
| 357 |
When nursing becomes transdisciplinary: promoting health in cancer experience, a collaboration between nurses and professional educators at an oncology center
|
Clementi, S.
|
|
|
28 |
S6 |
p. vi109
|
artikel
|
| 358 |
Whole-exome sequencing analysis identifies recurrent mutation rate in BAP1 gene in intrahepatic cholangiocarcinoma patients exposed to asbestos
|
Brandi, G.
|
|
|
28 |
S6 |
p. vi47
|
artikel
|
| 359 |
Worsening of quality of life (QoL), cognitive functions (CF) and psychological status (PSY) can predict radiologic progressive disease (RPD) in glioblastoma (GBM) patients (PTS) treated with radiation therapy (RT) and temozolomide (TMZ): a mono-institutional prospective study
|
Bergo, E.
|
|
|
28 |
S6 |
p. vi76
|
artikel
|
Tijdschrift beschrijving